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Abstract
Pre-symptomatic transmission can be a key determinant ofBackground: 
the effectiveness of containment and mitigation strategies for infectious
diseases, particularly if interventions rely on syndromic case finding. For
COVID-19, infections in the absence of apparent symptoms have been
reported frequently alongside circumstantial evidence for asymptomatic or
pre-symptomatic transmission. We estimated the potential contribution of
pre-symptomatic cases to COVID-19 transmission.
 
 Using the probability for symptom onset on a given day inferredMethods:
from the incubation period, we attributed the serial interval reported from
Shenzen, China, into likely pre-symptomatic and symptomatic
transmission. We used the serial interval derived for cases isolated more
than 6 days after symptom onset as the no active case finding scenario and
the unrestricted serial interval as the active case finding scenario. We
reported the estimate assuming no correlation between the incubation
period and the serial interval alongside a range indicating alternative
assumptions of positive and negative correlation.
 
 We estimated that 23% (range accounting for correlation: 12 –Results:
28%) of transmissions in Shenzen may have originated from
pre-symptomatic infections. Through accelerated case isolation following
symptom onset, this percentage increased to 46% (21 – 46%), implying that
about 35% of secondary infections among symptomatic cases have been
prevented. These results were robust to using reported incubation periods
and serial intervals from other settings.
 
Pre-symptomatic transmission may be essential to considerConclusions: 
for containment and mitigation strategies for COVID-19.
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Introduction
Since its emergence in early December 2019, SARS-CoV-2 
has spread rapidly despite multiple layers of interventions 
designed to prevent a pandemic1. In less than two months the 
COVID-19 outbreak progressed from fewer than 300 cases 
across four countries to more than 100,000 cases in over 
100 countries2,3. COVID-19 infection in the absence of clini-
cal symptoms has been frequently described4–7 alongside anec-
dotal evidence for potential asymptomatic or pre-symptomatic 
transmission or transmission while symptoms were suppressed 
by fever-reducing and prescription-free medication8–11. In 
combination with highly non-specific and generally mild 
symptoms in most cases12, pre-symptomatic transmission of 
COVID-19 would substantially hinder control and mitigation 
efforts, which typically focus on rapid syndromic identifica-
tion and isolation of cases13,14. We thus estimated the possible 
extent of pre-symptomatic transmission to help inform infection 
control and mitigation plans.
Data
Multiple estimates for the COVID-19 incubation period and 
serial interval have been reported to date. While estimates for 
the incubation period are relatively similar, the serial interval is 
dependent on the local context, in particular local contact 
patterns and the presence of interventions, active case finding 
with subsequent isolation, in particular, that may right-censor 
the serial interval. As our base case, we used the estimates 
provided by Bi et al. derived from 391 cases and their 1286 
contacts as identified by the Shenzen Centre for Disease 
Control15. This study currently includes the most extensive 
investigation of the infector-infectee transmission dynamics in a 
single setting.
Methods
The probability of pre-symptomatic transmission can be 
expressed as the probability of onward transmission during 
one’s incubation period. Ideally, this probability could be 
estimated from individual-level observations on exposure, onset 
of symptoms and the transmission to others. However, such 
data remains largely unavailable and is inherently difficult to 
generate. Instead, we approximated this quantity from popu-
lation estimates of the density distribution of the incubation 
period and the serial interval. We did so by first using the 
incubation period density distribution to calculate the probabil-
ity of having developed symptoms on each day since infection 
and then using this to stratify the serial interval distribution, 
assumed to be a proxy for the generation time, into likely 
pre-symptomatic and symptomatic onward transmissions.
The observations of the incubation period and the serial interval 
may be correlated. In other words, individuals with a long 
incubation period may not have a serial interval of typical 
length but may be exactly those who have a long serial inter-
val, or alternatively, exactly those who have a short serial 
interval. To account for this, we also calculated the propor-
tion of pre-symptomatic transmission by randomly drawing 
from the incubation period and serial interval distributions and 
pairing samples not randomly, but aligning them either both in 
ascending or one in ascending and the other in descending order 
(rank ordering), before calculating the proportion of draws 
with a shorter serial interval than the incubation period. We 
report the estimates assuming no correlation accompanied by 
a range indicating estimates that assume positive and negative 
correlations.
We consider two scenarios: transmission with and transmission 
(largely) without active case finding to accelerate case isolation. 
For the no active case finding scenario we use the serial interval 
reported based on cases that were only isolated at least 6 days 
after their symptom onset; i.e. 8.0 days (95% empirical confidence 
interval (eCI): 4.7 – 11.3). For the active case finding scenario 
we used the overall serial interval; i.e. 6.3 days (95% eCI: 
0.9 – 16.9) (Figure 1). The incubation period in this study was on 
average 6.0 days (95% eCI: 1.3 – 17.2).
We also included sensitivity analyses. We used the reported 
mean incubation period (5.2 days (95% eCI: 1.1 – 14.3)) and 
serial interval (7.5 days (95% eCI: 2.5 – 15.3)) from the first 
425 cases in Wuhan province as an alternative scenario for 
a setting with no or limited active case finding16. Further, 
Nishiura et al. provide estimates of the serial interval from 
published reports across all affected countries, mostly including 
attempted rapid case finding and isolation17. We use their mean 
serial interval estimates based on high certainty transmission 
pairs (4.8 days (95% eCI: 1.1 – 9.6)) in combination with 
either the incubation time reported by Bi et al.15 or Li et al.16. 
We implemented all density distributions to match reported 
estimates and their distributions18.
We then calculated the effectiveness of case isolation in reducing 
the number of secondary cases during the symptomatic period 
(φ) Let x be the proportion of pre-symptomatic transmission 
in the absence of active case finding, and y the same proportion 
in the presence of active case finding. Then, y can be expressed 
as a function of x while accounting for a reduction φ in the 
symptomatic cases:
(1 – )
x
y =
x+ xφ
Solving for φ:
(1 – )
(1 – )1 –
x
–xy
=
x
φ = x y
y x
All analyses were done in R 3.6.319; codes and data are available 
online18.
Results
In the scenario of no active case finding and isolation before 
six days after symptom onset, and assuming uncorrelated 
serial interval and incubation period distributions, we estimate 
that 23% (range accounting for correlation: 12 – 28%) of 
onward transmissions in Shenzen have occurred during the 
pre-symptomatic period (Figure 2 and Table 1).
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Figure 1. Probability density functions for the reported incubation period and serial intervals underlying our estimates.
Figure 2. Estimated attribution of the serial interval into pre-symptomatic transmission and symptomatic transmission for (A) no active case 
finding and (B) active case finding and accelerated case isolation. These estimates assume uncorrelated incubation period and serial interval 
estimates from Shenzen.
Page 4 of 9
Wellcome Open Research 2020, 5:58 Last updated: 08 APR 2020
Table 1. Overview of scenarios tested and the corresponding estimates for the percentage 
of transmission that may be attributable to pre-symptomatic infections.
Scenario Active 
case 
finding
Serial 
interval  
(95% eCI)*
Incubation 
period  
(95% eCI)*
Estimated percentage of pre-symptomatic 
transmission if the incubation period and 
the serial interval are
Uncorrelated Fully correlated
Fully  
anti-correlated
Main 
analyses
No
Bi et al. Bi et al.
23% 12% 28%8.0 
(4.7 – 11.3) 
6.0 
(1.3 – 17.2)
Yes
Bi et al. Bi et al.
46% 21% 46%6.3 
(0.9 – 16.9)
6.0 
(1.3 – 17.2)
Sensitivity 
analyses
No
Li et al. Li et al.
27% 1% 32%7.5  
(2.5 – 15.3)
5.2 
(1.1 – 14.3)
Yes
Nishiura et al. Li et al.
48% 38% 47%4.8 
(1.1 – 9.6)
5.2 
(1.1 – 14.3)
Yes
Nishiura et al. Bi et al.
53% 66% 51%4.8 
(1.1 – 9.6)
6.0 
(1.6 – 14.0)
* A summary table of the parameters used and the underlying assumptions regarding the probability 
distributions used is publicly available18. The uncertainty ranges above are those of the simulated distributions 
of serial interval and incubation periods (instead of the mean or median of these parameters), and thus may 
be different from what is reported in the original articles. Note that serial intervals sampled for with and without 
active case finding scenarios were independent, i.e., based on separate sets of parameters.
Active case finding and subsequent accelerated isolation right 
censors the serial interval and thereby reduces the number of 
symptomatic onward transmissions. In Shenzen, the presence 
of active case finding increased the percentage pre-sympto-
matic among all transmissions to 46% (21 – 46%). Therefore, 
case isolation in Shenzen has on average reduced the number 
of secondary cases during the symptomatic period by 35% 
(42 – 59%) and hence the total number of secondary cases by 
27% (32 – 45%).
Both the sensitivity analyses for the scenario of limited to no 
active case finding and for the scenario of real-world effects of 
active case finding and isolation during the containment phase 
of the outbreak response are similar to the estimates in our main 
analysis (Table 1).
Conclusion
We estimated that without active case finding to accelerate 
isolation in Shenzen 12 to 28% of transmissions occurred 
during the pre-symptomatic period. We further estimated that 
active case finding reduced the number of secondary infections 
after symptom onset and thereby increased the percentage of 
pre-symptomatic transmissions to 21 to 46%. This implies that in 
Shenzen accelerated case isolation has prevented 35 – 60% of 
secondary cases among symptomatic infectees. These results 
were similar when alternative settings with and without 
accelerated case isolation were considered.
In addition to the mostly-mild and non-specific symptoms of 
COVID-19, a high contribution of pre-symptomatic cases to 
the transmission dynamics of COVID-19 could be part of the 
reason why controlling COVID-19 has been challenging 
and seems to have failed in many countries13. It implies that 
control and mitigation of COVID-19 may be substantially 
improved if also targeting pre-symptomatic infections. This 
may be achieved via social distancing interventions that do 
not rely on the identification of symptoms. Having 10 – 30% 
pre-symptomatic transmission also suggests that immediate 
isolation at symptom onset can at best prevent 70–90% of cases. 
However, immediate case isolation on the day of symptoms 
onset is unlikely. We also find that, based on parameters 
estimated under no active case finding scenarios, case isolation 
on days 1, 3 or 7 after symptom onset reduces the proportion 
of or preventable onward transmissions by syndromic case 
finding and isolation to approximately 60%, 50% and less 
than 20%, respectively (Figure 3). We find that in Shenzhen 
syndromic identification and isolation has prevented 35 – 60% 
of secondary cases from symptomatic infectees, which is in line 
with previous model-based estimates14.
Even for well-studied pathogens like influenza, there is a 
substantial amount of uncertainty in the contribution of asymp-
tomatic and pre-symptomatic infections to the transmission 
dynamics. For influenza, 10 – 20% of infections have been 
found to be asymptomatic but shedding, although at lower viral 
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Figure 3. Proportion of potentially preventable onward transmission by days after symptoms onset. These estimates are based on 
parameters from scenarios with no public health interventions.
loads20,21. For SARS, 7.5% of exposed and seroconverted health 
care workers were found to not have displayed symptoms 
although it is unclear if those were also effectively transmitting22. 
For COVID-19 the proportion of pre-symptomatic or asymp-
tomatic infections is likely much higher. During an outbreak 
aboard a cruise ship, 50% of passengers who tested positive 
were asymptomatic at sample collection and therefore may 
or may not have developed symptoms at some point later on6. 
Whether asymptomatic carriers are also infectious has not yet 
been clearly established. Our work is based on observations of 
eventually symptomatic cases and hence we implicitly assume 
that only those who will eventually become symptomatic can 
effectively transmit. If there is an additional role for asymp-
tomatic individuals in the transmission of COVID-19 this 
will further decrease the proportion of secondary infections 
attributable to symptomatic cases. Hence, our estimate that 
among those COIVD-19 cases who eventually will develop 
symptoms the pre-symptomatics substantially contribute to 
transmission is a conservative approximation for the contribution 
of individuals without symptoms to COVID-19 transmission.
A key limitation for this study is that we had to use population- 
level estimates rather than individual-level estimates for the 
incubation period and the serial interval. We address biases 
potentially arising from the correlation of the two estimates on 
the individual level by estimating the sensitivity of estimates to 
the assumption of positive or negative correlation. Additionally, 
our estimates are in essence estimating the proportion of 
pre-symptomatic transmission from the amount of overlap of 
the incubation period distribution and the serial interval 
distribution. If the heterogeneity observed in either distribu-
tion was originated in measurement bias rather than in actual 
between individual heterogeneity of the infection process, then 
we would overestimate the role of pre-symptomatic transmission. 
In our sensitivity analyses, we find similar estimates for other 
settings indicating that the observed heterogeneity in Shenzhen 
is unlikely to be purely an observation artefact. However, our 
study supports the World Health Organization’s prioritisation 
for epidemiological studies, ideally individual-level observa-
tions, to further enhance the evidence base around the role of 
pre-symptomatic transmission for COVID-1923.
In summary, we find that pre-symptomatic transmission may 
play a key role in the epidemiology of COVID-19. Given the 
relevance of pre-symptomatic transmission for control and 
mitigation efforts, additional studies are urgently needed to reduce 
the uncertainty in the role of pre-symptomatic transmission.
Data availability
Source data
This project does not involve any primary data collection. All 
data used are based on references 15, 16, and 17. More specifi-
cally:
nCoV_Incubation.csv (Digitized distribution of incubation period 
from 16)
nCoV_Serial.csv (Digitised distribution of serial interval from 16)
COVID-19 Serial Interval.csv (Detailed information on parameters 
used to reconstruct distributions of serial interval and incubation 
period from 15,16, and 17).
Underlying data
Zenodo: yangclaraliu/2019nCoV_proportion_asym: WOR 
Submission. https://doi.org/10.5281/zenodo.370994218.
This project contains the following underlying data:
•     COVID-19 Serial Interval.csv (Spreadsheet of extracted 
source data)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Software availability
Replication code is available from:
https://github.com/yangclaraliu/2019nCoV_proportion_asym
Archived source code at the time of publication: https://doi.
org/10.5281/zenodo.370994218.
License: CC0 1.0 Universal
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